Catalogue Number: AB02936-2.0-BT-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | NARC1; NARC-1; PC9; Proprotein convertase subtilisin/kexin type; Neural apoptosis-regulated convertase 1; Proprotein convertase 9; Subtilisin/kexin-like protease PC9 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 1 mg |
| Host name: | Mouse |
| Clone: | FAP2M21 |
| Isotype: | IgG2a |
| Immunogen: | The original antibody was generated by panning a fully human scFv phage display library with recombinant human PCSK9. Later on the scFv was transformed into a full length IgG antibody. |
| Application: | ELISA, FC, IF, FA, Blk, Inh |
Q8NBP7
PCSK9
255738
Purified
Recombinant Monoclonal
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
This antibody binds human PCSK9 with an extremely slow dissociation rate constant and exert its hypolipidemic effect by blocking PCSK9-LDLR interaction. The binding characterization of this antibody was done using ELISA. Bio-Layer Interferometry (BLI) analysis revealed that the full-length IgG1 antibody FAP2M21 binds to hPCSK9 with a KD as low as 1.42 nM, and a dramatically slow dissociation rate (koff, 4.68 x 10-6 s-1) (PMID: 33647772). This antibody was also used to analyze LDLR expressed on the surface of HepG2 cells using flow cytometry and immunofluorescence staining. This antibody potently inhibited PCSK9-induced reduction of LDL-C uptake in HepG2 cells, with an EC50 of 43.56 nM. When this antibody was injected in C57BL/6 mice expressing human PCSK9, it dose-dependently up-regulated hepatic LDLR levels, and concomitantly reduced serum LDL-C by 3.3% and 37.2%, respectively (PMID: 33647772).
This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.